rethinkTHC Search
Menu
Study breakdown

Cannabinoid Hyperemesis Syndrome in Adolescents: Diagnosis and Treatment Guide

Narrative ReviewModerate evidence
The takeaway

The best current evidence for treating acute pediatric cannabinoid hyperemesis syndrome suggests IV rehydration followed by low-dose haloperidol, with complete cannabis cessation as the only long-term solution.

Pediatricians, emergency medicine providers, parents of cannabis-using teens

Haloperidol 0.05 mg/kg recommended for acute treatment

What the researchers found

Current best evidence recommends IV rehydration and electrolyte correction, followed by haloperidol 0.05 mg/kg with or without a benzodiazepine for acute pediatric CHS. The only effective long-term treatment remains complete cessation of cannabinoid use.

Why it matters

CHS prevalence in adolescents continues to grow as cannabis becomes more accessible and potent. Clinicians need practical guidance because high-quality treatment evidence specific to pediatric populations is lacking.

The numbers in context

Haloperidol dose: 0.05 mg/kg IV; presenting features: cyclical nausea, emesis, abdominal pain, hot shower relief

How the study worked

Narrative review of current literature on adolescent CHS, covering diagnosis, pathophysiology, and treatment evidence.

What this study cannot tell us

High-quality treatment evidence for adolescent CHS remains lacking. Recommendations are based on limited data extrapolated partly from adult studies.

How to read the evidence

Narrative review providing practical guidance, but based on limited pediatric-specific evidence.

When this study was published

Published in 2022

The bigger picture

As adolescent cannabis use patterns evolve toward higher-potency products and more frequent use, CHS is likely to become an increasingly common pediatric emergency presentation.

Questions still open

  • Are there pharmacological treatments that could prevent CHS relapse in adolescents who cannot achieve cessation? Does the potency of cannabis products influence CHS severity in young people?

Common questions

How is cannabinoid hyperemesis syndrome treated in adolescents?
Current best evidence suggests IV rehydration, electrolyte correction, and haloperidol 0.05 mg/kg with or without a benzodiazepine. Complete cessation of cannabis use is the only known long-term treatment.
How do you diagnose CHS in teenagers?
The key features are cyclical nausea, vomiting, and abdominal pain in the context of chronic cannabis use, with symptom relief from hot showers being a characteristic finding.

Read the original research

Paediatric cannabinoid hyperemesis.

Current opinion in pediatrics, 34(5), 510-515

Citation

Lonsdale, Hannah; Wilsey, Michael J. (2022). Paediatric cannabinoid hyperemesis.. Current opinion in pediatrics, 34(5), 510-515. https://doi.org/10.1097/MOP.0000000000001157

Explore the wider topic